CRISPR IP - Navigating the Complexities

Introduction

The CRISPR IP saga has rolled on with no apparent easing of licensing considerations for those wishing to use CRISPR-Cas gene-editing systems and Toolgen showing preparedness to litigate if provoked to do so.

This new virtual classroom seminar will provide you with up-to-date information on relevant patent claims to aid licensing considerations over use of CRISPR-Cas systems in common use, especially as a foundation for gene modification in the therapeutic field.

Both the Broad ‘camp’ and CVC ‘camp’ (the University of California, the University of Vienna and Emmanuelle Charpentier) suffered disappointments at opposition oral proceedings in late 2025 but this does not mean the end of the road for either in securing claims from the European Patent Office (‘EPO’) of broad applicability to Cas9 use.

Toolgen’s litigation against Vertex and its associated CMOs accompanied by focus on patent claim coverage for delivery of Cas9 ribonucleoproteins (‘RNPs’) adds to the on-going IP complexity.

The session is suitable for anyone interested in keeping up to date with the CRISPR IP saga in Europe in relation to gene editing, including patent professionals in private practice or in corporate legal teams, tech transfer professionals, life science investors, researchers in academia or corporate research and members of corporate business teams.

Some technical knowledge of CRISPR-Cas systems in common use and basic patenting knowledge is assumed.

What You Will Learn

This live and interactive course will cover the following:

• Describe the current IP picture in Europe relating to both Type II and Type V CRISPR- Cas systems including key patents, ownership trends and recent developments
• Analyse and explain the strategic implications of the IP landscape for innovation and commercialisation, highlighting how patent rights, licensing requirements and ongoing litigation influence research, product development and market entry
• How to identify and evaluate the main considerations for different types of potential licensees
• A discussion of FAQs relating to licensing including negotiation strategies and common challenges for managing IP in the CRISPR field
• How to apply insights from the European CRISPR IP landscape to practical scenarios

Recording of live sessions: Soon after the Learn Live session has taken place you will be able to go back and access the recording - should you wish to revisit the material discussed.